Juming Yan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7591850/publications.pdf Version: 2024-02-01



Ιμμινίς Υλν

#	Article	IF	CITATIONS
1	Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells. Nature Immunology, 2017, 18, 1004-1015.	7.0	504
2	The NK cell granule protein NKG7 regulates cytotoxic granule exocytosis and inflammation. Nature Immunology, 2020, 21, 1205-1218.	7.0	110
3	MAIT Cells Promote Tumor Initiation, Growth, and Metastases via Tumor MR1. Cancer Discovery, 2020, 10, 124-141.	7.7	101
4	Interleukin (IL)-12 and IL-23 and Their Conflicting Roles in Cancer. Cold Spring Harbor Perspectives in Biology, 2018, 10, a028530.	2.3	94
5	Ciclopirox induces autophagy through reactive oxygen species-mediated activation of JNK signaling pathway. Oncotarget, 2014, 5, 10140-10150.	0.8	75
6	Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome. Oncolmmunology, 2019, 8, e1581530.	2.1	69
7	Control of Metastases via Myeloid CD39 and NK Cell Effector Function. Cancer Immunology Research, 2020, 8, 356-367.	1.6	60
8	Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis. Oncolmmunology, 2018, 7, e1445949.	2.1	46
9	Infiltrating Myeloid Cells Drive Osteosarcoma Progression via GRM4 Regulation of IL23. Cancer Discovery, 2019, 9, 1511-1519.	7.7	26
10	B591, a novel specific pan-PI3K inhibitor, preferentially targets cancer stem cells. Oncogene, 2019, 38, 3371-3386.	2.6	21
11	Experimental Lung Metastases in Mice Are More Effectively Inhibited by Blockade of IL23R than IL23. Cancer Immunology Research, 2018, 6, 978-987.	1.6	10
12	Identification of two novel inhibitors of mTOR signaling pathway based on high content screening. Cancer Chemotherapy and Pharmacology, 2013, 72, 799-808.	1.1	7
13	<i>ent</i> â€Kaurane Diterpenoids from <i>lsodon eriocalyx </i> var. <i>laxiflora</i> . Chinese Journal of Chemistry, 2012, 30, 1226-1230.	2.6	6
14	<scp>IL</scp> â€23 promotes the development of castrationâ€resistant prostate cancer. Immunology and Cell Biology, 2018, 96, 883-885.	1.0	4